QNRX vs. NXGL, IRIX, PETV, NXL, XAIR, NRXS, LFWD, VVOS, ICU, and BTCY
Should you be buying Quoin Pharmaceuticals stock or one of its competitors? The main competitors of Quoin Pharmaceuticals include NEXGEL (NXGL), IRIDEX (IRIX), PetVivo (PETV), Nexalin Technology (NXL), Beyond Air (XAIR), NeurAxis (NRXS), ReWalk Robotics (LFWD), Vivos Therapeutics (VVOS), SeaStar Medical (ICU), and Biotricity (BTCY). These companies are all part of the "medical equipment" industry.
Quoin Pharmaceuticals vs.
NEXGEL (NASDAQ:NXGL) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, community ranking, risk and valuation.
Quoin Pharmaceuticals has a net margin of 0.00% compared to NEXGEL's net margin of -52.60%. NEXGEL's return on equity of -71.19% beat Quoin Pharmaceuticals' return on equity.
2.2% of NEXGEL shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 20.5% of NEXGEL shares are owned by insiders. Comparatively, 3.7% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
NEXGEL has higher revenue and earnings than Quoin Pharmaceuticals. NEXGEL is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, NEXGEL and NEXGEL both had 2 articles in the media. Quoin Pharmaceuticals' average media sentiment score of 0.02 beat NEXGEL's score of -0.06 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.
Quoin Pharmaceuticals received 4 more outperform votes than NEXGEL when rated by MarketBeat users. Likewise, 55.56% of users gave Quoin Pharmaceuticals an outperform vote while only 50.00% of users gave NEXGEL an outperform vote.
NEXGEL has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
Summary
Quoin Pharmaceuticals beats NEXGEL on 7 of the 13 factors compared between the two stocks.
Get Quoin Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quoin Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:QNRX) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy QNRX Stock Free QNRX Stock Alerts